Otsuka Pharmaceutical, a firm that carries out R&D, produces products in its two core businesses which are pharmaceuticals for providing breakthrough treatments, agreed to acquire the measurement technology from Konica Minolta, a Japanese equipment and material manufacturer that operates globally. Financial terms were not disclosed. Through the acquisition of this SPFS technology higher diagnostic sensitivity is expected through Otsuka's development of unique biomarkers that have not been detectable by conventional testing methods. The technology is also expected to be used to support the research and development of innovative drugs within the Otsuka group of companies.